Uses of Amsibed 20

Drug Amsibed 20 is a drug is a lipid-lowering drug, the main ingredient is Simvastatin 20mg. The drug selectively inhibits the intestinal absorption of cholesterol and related plant sterols.

Treatment of primary hypercholesterolemia, or mixed dyslipidemia. Treatment of homozygous familial hypercholesterolemia as an adjunct to diet, and other lipid-lowering measures (e.g. LDL apheresis), or when these measures are not appropriate . Treatment of hypertriglyceridemia. Reduce cardiovascular morbidity and mortality in patients with atherosclerotic cardiovascular disease, or diabetes, with normal or elevated cholesterol levels. The drug is contraindicated in the following cases:
People with hypersensitivity to the active ingredient, or any of the excipients of the drug. Active liver disease, or unexplained persistent elevation of plasma transaminases. Pregnant and lactating women. Co-administration with potent inhibitors of CYP3A4 (eg, itraconazole; ketoconazole; posaconazole; HIV protease inhibitors; boceprevir; telaprevir; erythromycin; clarithromycin; telithromycin and nefazodone). Used in combination with cyclosporine, gemfibrozil; or danazol. Myopathy secondary to taking other lipid-lowering drugs.

2.1. How to take Amsibed 20 Amsibed 20 is a film-coated tablet, so it will be taken orally. This drug is taken orally as a single dose of 5 to 80 mg daily, administered for a period of not less than 4 weeks with a maximum dose of 80 mg daily, the patient should take in the evening. Take Amsibed 20 tablets whole with a large amount of filtered water, or boiled and cooled enough water. Patients need to apply a low cholesterol diet before taking Amsibed 20 and maintain it throughout the time of taking the drug. 2.2. Dosage of Amsibed 20 Use at a dose of 80 mg in patients with severe hypercholesterolemia, and at high risk of cardiovascular complications who do not meet treatment goals on lower doses, and when the expected benefit outweighs the risk. latent. Hypercholesterolemia: Patients should be on a standard cholesterol-lowering diet, and this diet should be continued during treatment with Amsibed 20. The usual initial dose is 10 to 20 mg/day. Patients who require a drastic reduction in LDL-C (below 45%) can start at 20 to 40 mg/day. Homozygous Familial Hypercholesterolemia: Based on the results of controlled clinical studies, the recommended initial dose is 40 mg daily. Amsibed 20 should be used as an adjunct to other lipid-lowering therapies (e.g. LDL apheresis) in these patients In patients receiving lomitapide concomitantly with simvastatin, and the dose of simvastatin should not exceed 40 mg per day. day. Cardiovascular prevention: The usual dose of Amsibed 20 is 20 to 40 mg per day. Drug therapy can be initiated concurrently with diet, and exercise, with dosage adjustment required if necessary. Concomitant treatment: Amsibed 20 is effective when used alone, or in combination with drugs that bind to bile acids. Should be taken more than 2 hours before, or more than 4 hours after taking drugs that bind to bile acids. In patients receiving Amsibed 20 concomitantly with fibrates, other than gemfibrozil, or fenofibrate, the dose of simvastatin should not exceed 10 mg daily. In patients receiving amiodarone, verapamil, amlodipine, and diltiazem concomitantly with Amsibed 20, the dose should not exceed 20 mg daily. Patients with renal impairment: No dose adjustment is required in patients with moderate renal impairment. In patients with severe renal impairment (creatinine clearance less than 30 ml/min), doses greater than 10 mg/day should be considered carefully and, if deemed necessary, used with caution. Elderly: No dose adjustment is required. Children: For children, and adolescents (boys Tanner stage II and older, and girls who have had periods for at least one year, ages 10 to 17) with heterozygous familial hypercholesterolemia death, the usual recommended initial dose is 10 mg. Children, and adolescents, who should be on a standard cholesterol-lowering diet before starting Amsibed 20 treatment, should continue this diet during treatment with Amsibed 20. The recommended dose is 10 to 40 mg daily. , the maximum dose is 40 mg per day. Dosage is individualized based on the intended therapeutic recommendations for the pediatric population. Dose adjustments need to be made at intervals of 4 weeks or more.

Nervous system disorders such as dizziness; headache. Gastrointestinal disorders such as abdominal pain; abdominal discomfort, upper abdominal pain, indigestion, or bloating, nausea, and vomiting. Skin and subcutaneous tissue disorders such as rash and itching. Musculoskeletal disorders such as arthralgia, muscle weakness, muscle spasms, musculoskeletal discomfort and neck pain, extremity pain. Local and systemic disorders such as asthenia, fatigue, peripheral edema. Psychiatric disorders such as sleep disturbances, insomnia Nervous system disorders such as headache and paresthesias.

Concomitant use with the following drugs that strongly inhibit CYP3A4 (eg itraconazole; ketoconazole; posaconazole; erythromycin; clarithromycin, telithromycin; HIV protease inhibitors; boceprevir; telaprevir; nefazodone) Gemfibrozil; Cyclosporin, or Danazo
Interactions with other drugs:
Fibrates: Vytorin should not be used in combination with fibrates until studies in patients with Amiodarone: myopathy and rhabdomyolysis are increased with concomitant use. with amiodarone. Cholestyramine: Concomitant use of cholestyramine reduces mean AUC of total ezetimibe (ezetimibe + ezetimibe glucuronide) Calcium channel blockers: The risk of myopathy, and rhabdomyolysis is increased with verapamil combination; diltiazem, or amlodipine The risk of myopathy may be slightly increased with concomitant use of fusidic acid. Colchicine: Myopathy and rhabdomyolysis have been reported with colchicine in patients with renal impairment. Careful clinical monitoring is recommended in patients receiving the combination. Patients should avoid drinking a lot of grapefruit juice when taking the drug